ERBB2 and breast carcinoma: Finally, another possible explanation could be that patients with hormone receptor-positive breast cancer benefit from extended periods of 5 to 10 years of endocrine therapy and patients with HER2-positive breast cancer receive anti-HER2-targeted therapies, whereas patients with triple-negative breast cancer rely predominantly on acute interventions such as surgery, chemotherapy and radiation owing to the absence of specific receptors (see Box 1).